{"id":66727,"date":"2026-05-29T21:05:57","date_gmt":"2026-05-29T13:05:57","guid":{"rendered":"https:\/\/flcube.com\/?p=66727"},"modified":"2026-05-29T21:05:59","modified_gmt":"2026-05-29T13:05:59","slug":"kexing-pharmaceutical-and-sinotherapeutics-partner-to-commercialize-tofacitinib-extended-release-tablets-in-kuwait-and-mexico","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=66727","title":{"rendered":"Kexing Pharmaceutical and Sinotherapeutics Partner to Commercialize Tofacitinib Extended-Release Tablets in Kuwait and Mexico"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\"><strong>Kexing Pharmaceutical<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/688136:SHA\">SHA: 688136<\/a>) and <strong>Sinotherapeutics Inc.<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/688247:SHA\">SHA: 688247<\/a>) have announced a <strong>joint commercialization agreement<\/strong> for <strong>tofacitinib citrate extended-release tablets<\/strong> in <strong>Kuwait and Mexico<\/strong>. The drug, developed by Sinotherapeutics, received <strong>U.S. approval in September 2025<\/strong> and represents a strategic expansion of Chinese pharmaceutical companies into international markets.<\/p>\n\n\n\n<h2 id=\"h-partnership-structure-amp-product-details\" class=\"wp-block-heading\">Partnership Structure &amp; Product Details<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Parameter<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Partners<\/strong><\/td><td>Kexing Pharmaceutical and Sinotherapeutics Inc.<\/td><\/tr><tr><td><strong>Product<\/strong><\/td><td>Tofacitinib citrate extended-release tablets<\/td><\/tr><tr><td><strong>Territories<\/strong><\/td><td>Kuwait and Mexico<\/td><\/tr><tr><td><strong>Commercial Model<\/strong><\/td><td>Joint commercialization<\/td><\/tr><tr><td><strong>U.S. Approval<\/strong><\/td><td>September 2025<\/td><\/tr><tr><td><strong>Dosing Regimen<\/strong><\/td><td>Once-daily (extended-release formulation)<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 id=\"h-drug-profile-amp-clinical-indications\" class=\"wp-block-heading\">Drug Profile &amp; Clinical Indications<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Drug Class:<\/strong> Oral small-molecule JAK inhibitor<\/li>\n\n\n\n<li><strong>Therapeutic Category:<\/strong> Disease-modifying antirheumatic drug (DMARD)<\/li>\n\n\n\n<li><strong>Primary Indication:<\/strong> Adult patients with moderate to severe active rheumatoid arthritis (RA) who have had inadequate response or intolerance to methotrexate<\/li>\n\n\n\n<li><strong>Additional Indications:<\/strong><\/li>\n\n\n\n<li>Psoriatic arthritis<\/li>\n\n\n\n<li>Ankylosing spondylitis<\/li>\n\n\n\n<li><strong>Key Differentiation:<\/strong> Extended-release formulation enables once-daily dosing, significantly improving patient adherence compared to immediate-release alternatives<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-market-opportunity-analysis\" class=\"wp-block-heading\">Market Opportunity Analysis<\/h2>\n\n\n\n<h3 id=\"h-kuwait-rheumatology-market\" class=\"wp-block-heading\">Kuwait Rheumatology Market<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Patient Population:<\/strong> Estimated 25,000-30,000 RA patients with significant unmet need for advanced therapies<\/li>\n\n\n\n<li><strong>Current Landscape:<\/strong> Limited access to newer JAK inhibitors due to import restrictions and pricing barriers<\/li>\n\n\n\n<li><strong>Regulatory Pathway:<\/strong> Streamlined approval process for products with U.S. FDA approval<\/li>\n\n\n\n<li><strong>Pricing Advantage:<\/strong> Chinese manufacturing enables competitive pricing against originator products<\/li>\n<\/ul>\n\n\n\n<h3 id=\"h-mexico-autoimmune-disease-market\" class=\"wp-block-heading\">Mexico Autoimmune Disease Market<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Market Size:<\/strong> $450-500 million annual market for RA and related autoimmune conditions<\/li>\n\n\n\n<li><strong>Access Challenges:<\/strong> High out-of-pocket costs limit biologic and advanced small molecule adoption<\/li>\n\n\n\n<li><strong>Generic Competition:<\/strong> Established generic methotrexate market creates need for next-line therapies<\/li>\n\n\n\n<li><strong>Distribution Network:<\/strong> Partnership leverages existing Kexing\/Sinotherapeutics infrastructure in Latin America<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-strategic-implications-for-chinese-pharma\" class=\"wp-block-heading\">Strategic Implications for Chinese Pharma<\/h2>\n\n\n\n<h3 id=\"h-international-expansion-strategy\" class=\"wp-block-heading\">International Expansion Strategy<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Market Selection:<\/strong> Kuwait and Mexico represent strategic entry points with favorable regulatory environments<\/li>\n\n\n\n<li><strong>Product Differentiation:<\/strong> Extended-release formulation provides clinical advantage over existing options<\/li>\n\n\n\n<li><strong>Partnership Model:<\/strong> Joint commercialization reduces individual company risk while leveraging complementary strengths<\/li>\n\n\n\n<li><strong>Global Ambition:<\/strong> Builds on U.S. approval to establish international presence<\/li>\n<\/ul>\n\n\n\n<h3 id=\"h-competitive-positioning\" class=\"wp-block-heading\">Competitive Positioning<\/h3>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Product<\/th><th>Originator<\/th><th>Current Status in Target Markets<\/th><th>Chinese Partners&#8217; Advantage<\/th><\/tr><\/thead><tbody><tr><td><strong>Tofacitinib IR<\/strong><\/td><td>Pfizer (Xeljanz)<\/td><td>Available but limited access<\/td><td>Once-daily dosing improves adherence<\/td><\/tr><tr><td><strong>Baricitinib<\/strong><\/td><td>Lilly\/Incyte<\/td><td>Limited availability<\/td><td>Established safety profile with extended-release benefits<\/td><\/tr><tr><td><strong>Upadacitinib<\/strong><\/td><td>AbbVie (Rinvoq)<\/td><td>Premium pricing restricts access<\/td><td>Competitive pricing with proven efficacy<\/td><\/tr><tr><td><strong>Tofacitinib XR<\/strong><\/td><td>Sinotherapeutics\/Kexing<\/td><td><strong>New market entry<\/strong><\/td><td><strong>Optimized dosing + local manufacturing cost advantages<\/strong><\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 id=\"h-development-amp-regulatory-timeline\" class=\"wp-block-heading\">Development &amp; Regulatory Timeline<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>U.S. Approval:<\/strong> September 2025 (provides regulatory credibility for international filings)<\/li>\n\n\n\n<li><strong>Kuwait Registration:<\/strong> Expected Q3-Q4 2026<\/li>\n\n\n\n<li><strong>Mexico Registration:<\/strong> Expected Q4 2026-Q1 2027<\/li>\n\n\n\n<li><strong>Commercial Launch:<\/strong> Anticipated 2027 in both territories<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Forward-Looking Statements<\/strong><br>This brief contains forward-looking statements regarding regulatory approvals, market access, and commercial potential for tofacitinib extended-release tablets. Actual results may differ due to risks including regulatory decisions, market competition, pricing negotiations, and geopolitical factors affecting international pharmaceutical trade.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Kexing Pharmaceutical (SHA: 688136) and Sinotherapeutics Inc. (SHA: 688247) have announced a joint commercialization agreement&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10],"tags":[65,3625,1229,4762,3683],"class_list":["post-66727","post","type-post","status-publish","format-standard","hentry","category-company","category-deals","tag-auto-immune","tag-kexing-biopharm","tag-sha-688136","tag-sha-688247","tag-sinotherapeutics"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v27.7) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Kexing Pharmaceutical and Sinotherapeutics Partner to Commercialize Tofacitinib Extended-Release Tablets in Kuwait and Mexico - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Kexing Pharmaceutical (SHA: 688136) and Sinotherapeutics Inc. (SHA: 688247) have announced a joint commercialization agreement for tofacitinib citrate extended-release tablets in Kuwait and Mexico. The drug, developed by Sinotherapeutics, received U.S. approval in September 2025 and represents a strategic expansion of Chinese pharmaceutical companies into international markets.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=66727\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Kexing Pharmaceutical and Sinotherapeutics Partner to Commercialize Tofacitinib Extended-Release Tablets in Kuwait and Mexico\" \/>\n<meta property=\"og:description\" content=\"Kexing Pharmaceutical (SHA: 688136) and Sinotherapeutics Inc. (SHA: 688247) have announced a joint commercialization agreement for tofacitinib citrate extended-release tablets in Kuwait and Mexico. The drug, developed by Sinotherapeutics, received U.S. approval in September 2025 and represents a strategic expansion of Chinese pharmaceutical companies into international markets.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=66727\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-05-29T13:05:57+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-05-29T13:05:59+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=66727#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=66727\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Kexing Pharmaceutical and Sinotherapeutics Partner to Commercialize Tofacitinib Extended-Release Tablets in Kuwait and Mexico\",\"datePublished\":\"2026-05-29T13:05:57+00:00\",\"dateModified\":\"2026-05-29T13:05:59+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=66727\"},\"wordCount\":447,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Auto-immune\",\"Kexing Biopharm\",\"SHA: 688136\",\"SHA: 688247\",\"Sinotherapeutics\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=66727#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=66727\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=66727\",\"name\":\"Kexing Pharmaceutical and Sinotherapeutics Partner to Commercialize Tofacitinib Extended-Release Tablets in Kuwait and Mexico - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-05-29T13:05:57+00:00\",\"dateModified\":\"2026-05-29T13:05:59+00:00\",\"description\":\"Kexing Pharmaceutical (SHA: 688136) and Sinotherapeutics Inc. (SHA: 688247) have announced a joint commercialization agreement for tofacitinib citrate extended-release tablets in Kuwait and Mexico. The drug, developed by Sinotherapeutics, received U.S. approval in September 2025 and represents a strategic expansion of Chinese pharmaceutical companies into international markets.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=66727#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=66727\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=66727#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Kexing Pharmaceutical and Sinotherapeutics Partner to Commercialize Tofacitinib Extended-Release Tablets in Kuwait and Mexico\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Kexing Pharmaceutical and Sinotherapeutics Partner to Commercialize Tofacitinib Extended-Release Tablets in Kuwait and Mexico - Insight, China&#039;s Pharmaceutical Industry","description":"Kexing Pharmaceutical (SHA: 688136) and Sinotherapeutics Inc. (SHA: 688247) have announced a joint commercialization agreement for tofacitinib citrate extended-release tablets in Kuwait and Mexico. The drug, developed by Sinotherapeutics, received U.S. approval in September 2025 and represents a strategic expansion of Chinese pharmaceutical companies into international markets.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=66727","og_locale":"en_US","og_type":"article","og_title":"Kexing Pharmaceutical and Sinotherapeutics Partner to Commercialize Tofacitinib Extended-Release Tablets in Kuwait and Mexico","og_description":"Kexing Pharmaceutical (SHA: 688136) and Sinotherapeutics Inc. (SHA: 688247) have announced a joint commercialization agreement for tofacitinib citrate extended-release tablets in Kuwait and Mexico. The drug, developed by Sinotherapeutics, received U.S. approval in September 2025 and represents a strategic expansion of Chinese pharmaceutical companies into international markets.","og_url":"https:\/\/flcube.com\/?p=66727","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-05-29T13:05:57+00:00","article_modified_time":"2026-05-29T13:05:59+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=66727#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=66727"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Kexing Pharmaceutical and Sinotherapeutics Partner to Commercialize Tofacitinib Extended-Release Tablets in Kuwait and Mexico","datePublished":"2026-05-29T13:05:57+00:00","dateModified":"2026-05-29T13:05:59+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=66727"},"wordCount":447,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Auto-immune","Kexing Biopharm","SHA: 688136","SHA: 688247","Sinotherapeutics"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=66727#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=66727","url":"https:\/\/flcube.com\/?p=66727","name":"Kexing Pharmaceutical and Sinotherapeutics Partner to Commercialize Tofacitinib Extended-Release Tablets in Kuwait and Mexico - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-05-29T13:05:57+00:00","dateModified":"2026-05-29T13:05:59+00:00","description":"Kexing Pharmaceutical (SHA: 688136) and Sinotherapeutics Inc. (SHA: 688247) have announced a joint commercialization agreement for tofacitinib citrate extended-release tablets in Kuwait and Mexico. The drug, developed by Sinotherapeutics, received U.S. approval in September 2025 and represents a strategic expansion of Chinese pharmaceutical companies into international markets.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=66727#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=66727"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=66727#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Kexing Pharmaceutical and Sinotherapeutics Partner to Commercialize Tofacitinib Extended-Release Tablets in Kuwait and Mexico"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/66727","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=66727"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/66727\/revisions"}],"predecessor-version":[{"id":66730,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/66727\/revisions\/66730"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=66727"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=66727"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=66727"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}